Stock Report

Strides Partners with Ascent Capital to Unlock Value in Pivot Path

Posted On : 2026-06-27 19:37:29( TIMEZONE : IST )

Strides Pharma Science Limited (BSE: 532531, NSE: STAR) today announced a strategic investment by a consortium led by Ascent Capital, along with coinvestor Vintage Classic, in its wholly owned subsidiary, Pivot Path Private Limited ("Pivot Path").

The transaction values Pivot Path at ~₹2,300m on a post-money basis, enables Strides to realise ~₹1,000m while retaining a ~20% stake, and includes a primary capital infusion of ₹500 million to accelerate Pivot Path's next phase of growth.

The transaction reflects Strides' strategy of creating, scaling and unlocking value from highpotential businesses while retaining participation in their future growth. It also strengthens the Company's balance sheet and provides growth capital for Pivot Path to pursue its expansion strategy.

Pivot Path originated within Arco Lab Private Limited, Strides' Global Capability Centre (GCC), where it developed capabilities across life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services. As demand from external pharmaceutical and life sciences companies grew, the business evolved into an independent platform serving industry-leading customers. To support its next phase of growth, serve global customers effectively, build agentic-AI platforms, and enable access to external capital, the business was carved out into Pivot Path pursuant to a Scheme of Arrangement approved by the Hon'ble National Company Law Tribunal (NCLT) in May 2026.

Following completion of the transaction Pivot Path shall be reclassified as an Associate of the Company.

The transaction has been undertaken based on an independent valuation conducted by a SEBIregistered merchant banker, reflecting the strength of Pivot Path's differentiated capabilities, established customer relationships and long-term growth potential.

Pivot Path has established a profitable operating platform serving specialised, high-value segments within the life sciences industry. For FY26, the carved-out business reported revenue of ₹1,447 million (including revenues for services rendered to Strides) and EBITDA of ₹169 million, demonstrating its operating scale and growth trajectory.

Badree Komandur, MD & Group CEO of Strides, commented on the transaction and said, "Pivot Path exemplifies Strides' proven capability to identify, incubate and scale high-potential businesses. Over the past years, we have built a platform with specialised capabilities, a growing customer base and a strong foundation for future growth.

As the business enters its next phase, we believe this is the right time to bring in a strategic investment partner with the expertise and capital to accelerate its growth. This transaction unlocks value for Strides, provides Pivot Path with the resources to scale independently, and allows Strides to retain meaningful participation in its future success.

We are delighted to partner with Ascent Capital and its investor consortium, whose experience in building high-growth businesses will support Pivot Path's long-term ambitions."

Raja Kumar, Managing Director & Founder of Ascent Capital, commented on the transaction and said, "Pivot Path brings deep domain expertise across the core, non-discretionary segments of the pharmaceutical industry, capabilities that have been rigorously honed within the Strides stable.

As an Independent entity, Pivot Path is exceptionally well positioned to combine the power of technology and Agentic-AI with its 400+ subject matter experts in building purpose -built solutions that enable global customers to manage their compliance, digital transformation, and drug safety requirements with greater speed, precision, cost effectiveness and confidence.

We are excited to partner with Pivot Path's accomplished management team as the company enters its next phase of growth in one of the most dynamic environments the industry has seen."

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 1083.15 as compared to the previous close of Rs. 1110.80. The total number of shares traded during the day was 4086 in over 441 trades.

The stock hit an intraday high of Rs. 1118.60 and intraday low of 1073.50. The net turnover during the day was Rs. 4494438.00.